Comparative assessment of deferiprone and deferasirox in thalassemia major patients in the first two decades-single centre experience

Mathew Zachariah, Surekha Tony, Wafa Bashir, Abdulhakim Al Rawas, Yasser Wali, Anil Pathare

Research output: Contribution to journalArticle

6 Citations (Scopus)


Iron overload is mainly responsible for the morbidity and mortality in patients with beta thalassemia major (TM). Our aim was to compare treatment outcomes with oral iron chelators, deferiprone (DFP), and deferasirox (DFX) in the first two decades on therapy. Seventy patients with TM (mean age ± SD, 7.9 ± 4.2; range 1.5-17 years) attending the pediatric day care unit for regular transfusional support were enrolled in this cross-sectional cohort study. The patients were treated either with DFP at the dose of 75-100 mg/kg/d in three divided doses after food or DFX at the dose of 25-40 mg/kg/d as single dose before food. Mean serum ferritin (±SD) was lower in patients below 10 years (n = 44) at 1283 (±600) ng/mL when compared with patients ≥10 years (n = 19) at 1546 (±589) ng/mL. There was no significant difference in mean serum ferritin (±SD) level in patients receiving DFP (1360 ± 589) versus DFX (1260 ± 641) in this cohort, P > 0.05. 67% of the patients had Vitamin D deficiency (

Original languageEnglish
Pages (from-to)104-112
Number of pages9
JournalPediatric Hematology and Oncology
Issue number2
Publication statusPublished - Mar 2013



  • Beta thalassemia major
  • Deferasirox
  • Deferiprone
  • Ferritin
  • Iron overload

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this